Literature DB >> 28636845

Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients.

Edward B Garon1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28636845     DOI： 10.1056/NEJMe1705692

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  16 in total

Review 1.  Integrative Pharmacology: Advancing Development of Effective Immunotherapies.

Authors:  Mohammad Tabrizi; Daping Zhang; Vaishnavi Ganti; Glareh Azadi
Journal:  AAPS J       Date:  2018-04-27       Impact factor: 4.009

2.  Companion and complementary diagnostics for first-line immune checkpoint inhibitor treatment in non-small cell lung cancer.

Authors:  Jan Trøst Jørgensen; Karsten Bork Nielsen
Journal:  Transl Lung Cancer Res       Date:  2018-04

3.  Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.

Authors:  Zhibo Zhang; Fan Zhang; Fang Yuan; Ye Li; Junxun Ma; Qiuxiang Ou; Zhefeng Liu; Bo Yang; Lijie Wang; Haitao Tao; Sujie Zhang; Xiaoyan Li; Xiaoyu Zhi; Xiangwei Ge; Hua Bao; Xue Wu; Yi Hu; Jinliang Wang
Journal:  Ther Adv Med Oncol       Date:  2020-11-05       Impact factor: 8.168

4.  Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma.

Authors:  Ying Li; Wenbin Jiang; Tianhao Li; Mengyue Li; Xin Li; Zheyang Zhang; Sainan Zhang; Yixin Liu; Wenyuan Zhao; Yunyan Gu; Lishuang Qi; Lu Ao; Zheng Guo
Journal:  J Transl Med       Date:  2020-01-14       Impact factor: 5.531

Review 5.  Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges.

Authors:  Sridhar Nimmagadda
Journal:  Cancers (Basel)       Date:  2020-10-29       Impact factor: 6.639

Review 6.  The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?

Authors:  Rossana Franzin; Giuseppe Stefano Netti; Federica Spadaccino; Camillo Porta; Loreto Gesualdo; Giovanni Stallone; Giuseppe Castellano; Elena Ranieri
Journal:  Front Immunol       Date:  2020-10-08       Impact factor: 7.561

7.  The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?

Authors:  Amy L Cummings; Edward B Garon
Journal:  Cancer Biol Med       Date:  2017-11       Impact factor: 4.248

8.  PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study.

Authors:  Giulia Bertolini; Luca Bergamaschi; Andrea Ferrari; Salvatore L Renne; Paola Collini; Cecilia Gardelli; Marta Barisella; Giovanni Centonze; Stefano Chiaravalli; Cinzia Paolino; Massimo Milione; Maura Massimino; Michela Casanova; Patrizia Gasparini
Journal:  BMC Cancer       Date:  2018-06-13       Impact factor: 4.430

Review 9.  Cardiotoxicity of immune checkpoint inhibitors.

Authors:  Gilda Varricchi; Maria Rosaria Galdiero; Giancarlo Marone; Gjada Criscuolo; Maria Triassi; Domenico Bonaduce; Gianni Marone; Carlo Gabriele Tocchetti
Journal:  ESMO Open       Date:  2017-10-26

Review 10.  Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle.

Authors:  Imke H Bartelink; Ella F Jones; Sheerin K Shahidi-Latham; Pei Rong Evelyn Lee; Yanan Zheng; Paolo Vicini; Laura van 't Veer; Denise Wolf; Andrei Iagaru; Deanna L Kroetz; Brendan Prideaux; Cornelius Cilliers; Greg M Thurber; Zena Wimana; Geraldine Gebhart
Journal:  Clin Pharmacol Ther       Date:  2018-10-06       Impact factor: 6.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.